PsiOxus Therapeutics Ltd.
Harnessing the power of evolution to develop oncolytic viruses
This article was originally published in Start Up
Harnessing the power of Darwinian natural selection to find therapeutic oncolytic adenoviruses is one of the aims of the Oxford, UK-based start-up PsiOxus Therapeutics Ltd. Another is to develop the first therapies for the wasting syndromes cachexia and sarcopenia.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.